BTK and B-cell chronic lymphocytic leukemia: NX-2127, developed by Nurix Therapeutics, degrades Bruton’s Tyrosine Kinase (BTK) and is currently in Phase 1 trials for B-cell malignancies, including chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) [7].